An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

Exclusion Criteria

• •1. Allergic to the investigative product or any ingredient in the investigative product.
• •2. Past or current malignancy, except for cutaneous non-metastatic basal cell carcinoma or squamous cell carcinoma that has been adequately treated or removed
• •3. The subject currently has a central nervous system (CNS) disease that may affect the assessment of NMOSD;
• •4. Severe and uncontrolled conditions that the investigator determines may affect subjects' safety, trial compliance, evaluation of the end point, or the need to use medications not permitted in the protocol;
• •5. The investigator judges that the subject has a disease that affects the absorption, distribution, metabolism and excretion of the drug;
• •6. The subjects had any major clinical infection and was hospitalized or treated with parenteral antibiotics within 1 month before screening; Or other infections that investigator thought might aggravate as a result of participating in the study;
• •7. The subject may have an active, latent or undertreated Mycobacterium tuberculosis (ie, tuberculosis \[TB\]) infection, defined as follows:
• •* The result of QuantiFERON-TB Gold (QFT Gold test) was positive or the result of T-SPOT.TB was positive within 3 months before screening/screening period.
• •* Or chest imaging examinations suggest the presence of active tuberculosis infection within 3 months before screening / during the screening period;
• •* The result of QuantiFERON-TB Gold (QFT Gold test) was positive or the result of T-SPOT.TB was positive within 3 months before screening/screening period.
• •* Or chest imaging examinations suggest the presence of active tuberculosis infection within 3 months before screening / during the screening period;
• •8. Positive laboratory tests related to human immunodeficiency virus (HIV) or hepatitis B virus or hepatitis C virus;
• •9. Have received BTK inhibitors (e.g. ibrutinib) at any time in the past.
• •10. Received B-cell targeted therapy (such as rituximab) within 12 weeks before the first administration.
• •11. Received biological agents such as eculizumab, tocilizumab, Satralizumab, Alemtuzumab, Natalizumab within 12 weeks before the first administration;
• •12. Subjects who may receive any live attenuated vaccine during the screening period or have received any live virus vaccine within 8 weeks prior to initial administration;
• •13. Any concomitant disease other than NMOSD that requires glucocorticoid therapy (oral or IV) within the 6 months prior to screening.
• •14. Abnormal and clinically significant ECG examination during screening.
• •15. Alanine glutamate aminotransferase (ALT)\>2 times the upper limit of normal (ULN) and/or glutamate aspartate aminotransferase (AST)\>2 times ULN and/or bilirubin\>2 times ULN during the screening period ULN;
• •16. Abnormal white blood cell count, neutrophil count, lymphocyte count, or platelet count during the screening period are considered unsuitable for participating in the study after the investigator's assessment (refer to the following criteria):
• •* Hemoglobin \<100 g/L or hematocrit \<30%;
• •* White blood cell (WBC) count\<3.0×109/L (\<3000/mm3) or ANC\<1.2×109/L (\<1200/mm3);
• •* Lymphocytes \<0.8×109/L (\<800/mm3);
• •* Platelet count\<100×109/L (\<100,000/mm3)
• •17. eGFR≤60 ml/min (calculated according to Cockcroft-Gault) or receiving dialysis during the screening period.
• •18. Unable to undergo MRI scans. History of clinically significant CNS trauma (e.g. traumatic brain injury, cerebral contusion, spinal cord compression)
• •19. Pregnant or breastfeeding women;
• •20. Use of an investigational drug or other experimental therapy within 4 weeks, 5 pharmacokinetic half-lives, or the duration of biological effect (whichever is longer) prior to screening.
• •21. Any other conditions in which the investigator or sponsor believes that the subject is not suitable for inclusion in the study.
• •\-